Fig. 1
From: DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment
DRP2 expression was upregulated in LUAD tissues and correlated with aggressive clinical features. (A) An investigation into the expression of DRP2 across various cancer types was conducted utilizing the TCGA database. (B) Kaplan-Meier survival curves show the effect of DRP2 on OS in LC, LUAD, and LUSC. (C,D) To further analyze DRP2 mRNA expression, the TCGA database was employed to compare unpaired (C) and paired (D) samples from LUAD and normal tissues. (E) The expression of DRP2 in LUAD was examined using GSE31210 database. (F–H) DRP2 mRNA expression (F) in tumor tissue (“ T “) and pairs of normal lung epithelial tissue (“N”) from 31 LUAD patients, and DRP2 protein expression and quantification (G,H) were assessed in twelve representative patient pairs. (I) DRP2 immunohistochemical staining of tumor tissue and paired normal tissue in two typical LUAD patients. (J–K) Association of DRP2 with clinical staging. *P < 0.05, **P < 0.01, ***P < 0.001 versus “N/normol” group. Scale bar = 50 μm.
